SAN DIEGO, Nov. 17, 2015 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company
developing novel oncology and drug-delivery therapies, today
announced it will be expanding its facilities by opening a
satellite office on Gateway Boulevard in South San Francisco. Halozyme is headquartered
in San Diego and currently has
approximately 200 employees.
"Given the company's focus in oncology and growth trajectory, a
satellite office in San Francisco
is an important step to help us attract additional talented team
members whose focus will be to expand our clinical programs and
advance towards our goal of commercializing our
investigational new drug, PEGPH20," said Helen Torley, president and CEO. "The Bay Area
satellite location will give us the ability to augment our already
strong San Diego work force."
In addition to the ongoing Phase 2 Study 202 of PEGPH20 in
combination with gemcitabine and ABRAXANE®
(nab-paclitaxel) in pancreatic cancer, and the Phase 1b/2 study of
PEGPH20 in combination with docetaxel in Non-Small Cell Lung Cancer
(NSCLC). Halozyme recently announced that it has initiated a
clinical trial for a phase 1b/2 study evaluating its
investigational new drug PEGPH20 in combination with
KEYTRUDA® (pembrolizumab) in NSCLC and Gastric Cancer.
Halozyme also plans to initiate a Phase 3 trial of PEGPH20 in
combination with gemcitabine and ABRAXANE®
(nab-paclitaxel) in pancreatic cancer by the end of Q1 2016.
PEGPH20 (PEGylated recombinant human hyaluronidase) targets
hyaluronan (HA), a glycosaminoglycan, which is a chain of natural
sugars throughout the body that can accumulate around cancer cells,
inhibiting other therapies. PEGPH20 is designed to degrade HA to
improve the access to tumor cells for chemotherapy, monoclonal
antibodies and other immuno-therapy agents. For more
information about these studies and other Halozyme news, please
visit http://www.halozyme.com/Newsroom.
About PEGPH20
PEGPH20 is an investigational PEGylated
form of Halozyme's proprietary recombinant human hyaluronidase
under clinical development for the potential systemic treatment of
tumors that accumulate hyaluronan.
FDA granted orphan drug designation to PEGPH20 for treatment of
pancreatic cancer and fast track for PEGPH20 in combination with
gemcitabine and nab-paclitaxel for the treatment of metastatic
pancreatic cancer. Additionally, the European Commission, acting on
the recommendation from the Committee for Orphan Medicinal Products
of the European Medicines Agency, designated investigational drug
PEGPH20 an orphan medicinal product for the treatment of pancreatic
cancer.
About Halozyme
Halozyme Therapeutics is a
biotechnology company focused on developing and commercializing
novel oncology therapies that target the tumor microenvironment.
Halozyme's lead proprietary program, investigational drug PEGPH20,
applies a unique approach to targeting solid tumors, allowing
increased access of co-administered cancer drug therapies to the
tumor. PEGPH20 is currently in development for metastatic
pancreatic cancer, non-small cell lung cancer, metastatic breast
cancer and has potential across additional cancers in combination
with different types of cancer therapies. In addition to its
proprietary product portfolio, Halozyme has established
value-driving partnerships with leading pharmaceutical companies
including Roche, Baxalta, Pfizer, Janssen and AbbVie for its drug
delivery platform, ENHANZE™, which enables biologics and small
molecule compounds that are currently administered intravenously to
be delivered subcutaneously. Halozyme is headquartered in
San Diego. For more information
visit www.halozyme.com.
Safe Harbor Statement
In addition to historical
information, the statements set forth above include forward-looking
statements (including, without limitation, statements concerning
the possible activity, benefits and attributes of PEGPH20, the
possible method of action of PEGPH20, its potential application to
improve cancer therapies and statements concerning future actions
relating to the development of PEGPH20) that involve risk and
uncertainties that could cause actual results to differ materially
from those in the forward-looking statements. The forward-looking
statements are typically, but not always, identified through use of
the words "believe," "enable," "may," "will," "could," "intends,"
"estimate," "anticipate," "plan," "predict," "probable,"
"potential," "possible," "should," "continue," and other words of
similar meaning. Actual results could differ materially from the
expectations contained in forward-looking statements as a result of
several factors, including unexpected expenditures and costs,
unexpected results or delays in development and regulatory review,
regulatory approval requirements, unexpected adverse events and
competitive conditions. These and other factors that may result in
differences are discussed in greater detail in the Company's
Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission on November 9,
2015.
Contacts:
Temre
Johnson
Halozyme Therapeutics
858-704-8275
media@halozyme.com
Logo -
http://photos.prnewswire.com/prnh/20100302/LA63139LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/halozyme-to-expand-with-a-satellite-office-in-san-francisco-300180536.html
SOURCE Halozyme Therapeutics, Inc.